The momentum for biotech initial public offerings has lessened the urgency for private companies to rely on deal-making as an exit strategy, but M&A remains one of the best ways to boost the stock price of public companies – both those being acquired and those acquiring – and for public investors to make a significant return on their investments.
A research report recently released by Leerink Partners analyst Joseph Schwartz predicts the top 10 takeout targets of 2014 and early 2015, with Alkermes PLChigh on the list. It...